Article
Oncology
Donghao Xu, Yu Liu, Wentao Tang, Lingsha Xu, Tianyu Liu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Jisheng Li, Jiemin Zhao, Lechi Ye, Wenju Chang, Jianmin Xu
Summary: This study examined the treatment patterns of regorafenib in patients with advanced metastatic colorectal cancer in China. The results showed that both regorafenib monotherapy and combination therapy provided some relief for patients, with regorafenib plus anti-PD-1 antibodies showing better progression-free survival and regorafenib plus chemotherapy yielding the greatest benefit in overall survival. The study also found no significant difference in adverse events among the three groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Reem D. Mahmood, Danielle Shaw, Tine Descamps, Cong Zhou, Robert D. Morgan, Saifee Mullamitha, Mark Saunders, Nerissa Mescallado, Alison Backen, Karen Morris, Ross A. Little, Susan Cheung, Yvonne Watson, James P. B. O'Connor, Alan Jackson, Geoff J. M. Parker, Caroline Dive, Gordon C. Jayson
Summary: Metastatic colorectal cancer patients receiving standard chemotherapy show changes in cell- and protein-based biomarkers, with no association to survival outcomes. However, an increase in the MRI imaging biomarker K-trans is associated with worse overall survival, indicating potential for directing molecularly targeted therapies.
Article
Oncology
Francesca Salvianti, Stefania Gelmini, Irene Mancini, Mario Pazzagli, Serena Pillozzi, Elisa Giommoni, Marco Brugia, Francesco Di Costanzo, Francesca Galardi, Francesca De Luca, Francesca Castiglione, Luca Messerini, Pamela Pinzani, Lorenzo Antonuzzo
Summary: Liquid biopsy, including cfDNA and CTCs, shows prognostic value in KRAS mutated mCRC. CTCs are a negative prognostic marker at baseline, while cfDNA is easily accessible for monitoring tumor mutations over time. In longitudinal monitoring, these two markers complement each other in assessing disease progression.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, Jay Morris, Qianqian Liu, Jenny A. Mendez, Tyler Curiel, Joel Michalek, Devalingam Mahalingam
Summary: This study compared the efficacy of VOR/HCQ and RGF in mCRC, showing that VOR/HCQ had a shorter median progression-free survival but no significant difference in median overall survival compared to RGF. Both treatments were tolerated by patients and showed improved anti-tumor immunity in mCRC.
BRITISH JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Takeshi Kato, Toshihiro Kudo, Yoshinori Kagawa, Kohei Murata, Hirofumi Ota, Shingo Noura, Junichi Hasegawa, Hiroshi Tamagawa, Katsuya Ohta, Masakazu Ikenaga, Susumu Miyazaki, Takamichi Komori, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Chu Matsuda, Taroh Satoh, Tsunekazu Mizushima, Yuko Ohno, Hirofumi Yamamoto, Yuichiro Doki, Hidetoshi Eguchi
Summary: A prospective study found that a daily dose of 120 mg of Regorafenib showed significant efficacy and safety in the treatment of colorectal cancer, which may be beneficial to specific patient populations.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung-Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim
Summary: This study investigated the dynamics of ctDNA in metastatic colorectal cancer patients treated with regorafenib. Higher baseline cfDNA concentration was associated with worse survival. After 2 cycles of treatment, majority of ctDNA mutations showed decreased VAF and were associated with longer progression-free survival. Reduction in ctDNA burden, as estimated by the sum of VAF, could predict treatment outcomes.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Elisa Conde, Julie Earl, Lorena Crespo-Toro, Carolina Blanco-Agudo, Edurne Ramos-Munoz, E. Macarena Rodriguez-Serrano, Jose Carlos Martinez avila, Laura Salinas-Munoz, Silvia Serrano-Huertas, Reyes Ferreiro, Mercedes Rodriguez-Garrote, Bruno Sainz, Bartomeu Massuti, Pilar Garcia Alfonso, Manuel Benavides, Enrique Aranda, Maria Laura Garcia-Bermejo, Alfredo Carrato
Summary: This study validated a range of serum miRNAs, SNPs, and Notch 1 expression as predictive biomarkers associated with response or toxicity to regorafenib therapy in colorectal cancer patients, offering potential for personalized treatment strategies in fragile patients with CRC.
Article
Oncology
Davide Brocco, Pasquale Simeone, Davide Buca, Pietro Di Marino, Michele De Tursi, Antonino Grassadonia, Laura De Lellis, Maria Teresa Martino, Serena Veschi, Manuela Iezzi, Simone De Fabritiis, Marco Marchisio, Sebastiano Miscia, Alessandro Cama, Paola Lanuti, Nicola Tinari
Summary: This study examined the prognostic and predictive value of blood circulating EVs in patients with mCRC. Increased concentrations of tumor-induced blood circulating EVs, specifically CD133+ EVs, were associated with poor clinical outcomes. These findings suggest that EVs may serve as potential biomarkers for risk stratification and treatment selection in mCRC.
Article
Oncology
Emaan Haque, Ibrahim N. Muhsen, Abdullah Esmail, Godsfavour Umoru, Charisma Mylavarapu, Veronica B. Ajewole, Maen Abdelrahim
Summary: This study retrospectively reviewed the data of metastatic colorectal cancer patients who received combination therapy of regorafenib and fluorouracil. The results showed that this treatment option could provide disease control for some patients without new adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Valentina Magri, Luca Marino, Chiara Nicolazzo, Angela Gradilone, Gianluigi De Renzi, Michela De Meo, Orietta Gandini, Arianna Sabatini, Daniele Santini, Enrico Cortesi, Paola Gazzaniga
Summary: This study aimed to evaluate the clinical value of circulating tumor cell (CTC) dynamics in metastatic colorectal cancer (mCRC) patients receiving first-line treatments. The CTC data from 218 patients were analyzed and four prognostic trajectories were identified. The study confirmed the clinical significance of CTC positivity and suggested that CTC trajectories are better prognostic indicators than CTC enumeration at baseline, providing potential biomarkers to monitor first-line treatments.
Article
Oncology
Pilar Garcia-Alfonso, Andres Munoz, Jeronimo Jimenez-Castro, Paula Jimenez-Fonseca, Carles Pericay, Federico Longo-Munoz, Carmen Reyna-Fortes, Guillem Argiles-Martinez, Beatriz Gonzalez-Astorga, Maria Jose Gomez-Reina, Ana Ruiz-Casado, Nuria Rodriguez-Salas, Rafael Lopez-Lopez, Alberto Carmona-Bayonas, Veronica Conde-Herrero, Enrique Aranda
Summary: The study assessed the early clinical experience with trifluridine/tipiracil in Spain and identified potential survival markers for refractory metastatic colorectal cancer. The findings endorsed the real-life efficacy and safety of trifluridine/tipiracil, highlighting specific factors such as tumor burden, liver metastasis, alkaline phosphatase levels, dose reductions, and neutrophil/lymphocyte ratio as survival markers for patients.
Article
Oncology
Xiaohui Sun, Xiao-Ou Shu, Qing Lan, Monika Laszkowska, Qiuyin Cai, Nathaniel Rothman, Wanqing Wen, Wei Zheng, Xiang Shu
Summary: This study identified potential protein biomarkers for colorectal cancer risk using proteomics technologies in a two-stage case-control study. A total of 27 circulating proteins were found to be nominally associated with CRC risk, and 6 of them were validated in a separate validation phase. This is the first study to evaluate over 1000 circulating proteins in prediagnostic blood samples for their associations with CRC risk in East Asians.
Article
Multidisciplinary Sciences
Hung-Chih Hsu, Kuo-Cheng Huang, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Tsai-Sheng Yang, Chien-Chih Chen, Yee Chao, Hao-Wei Teng
Summary: The study aimed to construct an algorithm for selecting the right patients for regorafenib in treating refractory metastatic colorectal cancer (mCRC).
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Clelia Coutzac, Isabelle Trouilloud, Artru Pascal, Julie Henriques, Therese Masson, Solene Doat, Olivier Bouche, Romain Coriat, Angelique Saint, Valerie Moulin, Dewi Vernerey, Claire Gallois, Christelle De La Fouchardiere, David Tougeron, Julien Taieb
Summary: It is still uncertain whether regorafenib or trifluridine/tipiracil should be administered first in heavily pre-treated metastatic colorectal cancer patients. A prospective multicenter real-world study found similar survival rates in the regorafenib and trifluridine-tipiracil groups. Using propensity score analysis, the trifluridine-tipiracil group had a significantly longer progression-free survival (PFS), while clinical outcomes seemed similar regardless of the treatment sequence.
CLINICAL COLORECTAL CANCER
(2022)
Article
Surgery
Maximilian Kloft, Jessica E. Ruisch, Gayatri Raghuram, Jake Emmerson, Matthew Nankivell, David Cunningham, William H. Allum, Ruth E. Langley, Heike I. Grabsch
Summary: This study analyzed the relationship between negative lymph node size and overall survival in esophageal cancer patients. It found that large negative lymph node size is associated with better survival and may serve as a new prognostic biomarker. Further studies are needed to confirm these findings and explore the underlying biological mechanisms.
Article
Pathology
Gianluca Tedaldi, Camilla Guerini, Davide Angeli, Daniela Furlan, Laura Libera, Marco Vincenzo Lenti, Federica Grillo, Matteo Fassan, Enrico Solcia, Fausto Sessa, Marco Paulli, Antonio Di Sabatino, Paola Ulivi, Alessandro Vanoli
Summary: This study analyzed the molecular landscape of poorly cohesive carcinomas in the small bowel (SB-PCCs) and found that TP53 and RHOA mutations, as well as KRAS amplification, were the most frequent gene alterations. Additionally, most SB-PCCs were associated with Crohn disease and exhibited a peculiar histology resembling appendiceal-type low-grade goblet cell adenocarcinoma. These findings contribute to a better understanding of the molecular characteristics of SB-PCCs.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Avani Athauda, Matthew Nankivell, Rupert Langer, Susan Pritchard, Ruth E. Langley, Katharina von Loga, Naureen Starling, Ian Chau, David Cunningham, Heike I. Grabsch
Summary: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Kaixin Yang, Wenyang Zhang, Linghui Zhong, Yinan Xiao, Sudhakar Sahoo, Matteo Fassan, Kang Zeng, Peter Magee, Michela Garofalo, Lei Shi
Summary: Lung cancer, the leading cause of cancer-related deaths worldwide, is driven by KRAS activation. This study identifies HIF1A-As2 as a KRAS-induced long non-coding RNA that promotes proliferation, epithelial-mesenchymal transition, and tumor propagation in non-small cell lung cancer. HIF1A-As2 activates MYC through epigenetic modifications, while KRAS induces HIF1A-As2 expression via MYC. Inhibition of HIF1A-As2 improves sensitivity to MYC-specific inhibitors and cisplatin treatment in lung tumors.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Oncology
Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjigian, Amy Qin, Jasmeet Singh, Ferdous Barlaskar, Yoshinori Kawaguchi, Geoffrey Ku
Summary: The DESTINY-Gastric02 trial is a phase 2 study evaluating the efficacy of trastuzumab deruxtecan in HER2-positive advanced gastric and gastro-oesophageal junction cancer. The results demonstrate clinically meaningful response rates, supporting its use as second-line therapy for these patients.
Article
Surgery
Michal Kawka, Tamara M. H. Gall, Fiona Hand, Scarlet Nazarian, David Cunningham, David Nicol, Long R. Jiao
Summary: This study retrospectively analyzed 60 cases of robotic pancreatoduodenectomy (RPD) and found a significant decrease in operative time after 21 RPD cases. This suggests that technical proficiency in RPD improves after a certain number of procedures have been performed.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Editorial Material
Oncology
Ian Chau
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Surgery
Imerio Angriman, Silvia Degasperi, Claudia Mescoli, Carmelo Lacognata, Claudia Armellin, Antonino Caruso, Federico Scognamiglio, Matteo Fassan, Renata D'Inca, Edoardo Savarino, Fabiana Zingone, Gaya Spolverato, Salvatore Pucciarelli, Romeo Bardini, Cesare Ruffolo, Marco Scarpa
Summary: This retrospective study analyzed the intestinal and systemic inflammation after surgery in Crohn's disease patients with strictures where the diseased bowel was left behind. The results showed that the intestinal inflammatory activity decreased even with the preservation of the diseased bowel, but the presence of the diseased bowel increased the risk of reoperation.
Article
Nutrition & Dietetics
Alice Zaramella, Diletta Arcidiacono, Daniele Nucci, Federico Fabris, Clara Benna, Salvatore Pucciarelli, Matteo Fassan, Alberto Fantin, Valli De Re, Renato Cannizzaro, Stefano Realdon
Summary: Esophageal adenocarcinoma (EAC) is a consequence of long-term gastroesophageal reflux, which leads to inflammation and could cause Barrett's esophagus (BE), the main risk factor for EAC development. The study aims to explore the esophageal microbial profile in patients with different stages of BE and EAC, and develop a score to predict cancer risk.
Meeting Abstract
Oncology
Neil McCafferty, Caroline Fong, Louise J. Barber, Andrew Woolston, Dimitrios Kleftogiannis, Taqia Rana, Susan Cromarty, Shannon Kidd, Ruwaida Begum, Ian Chau, Naureen Starling, David Cunningham, Marco Gerlinger
Meeting Abstract
Oncology
Marco Gerlinger, Anderley Gordon, Louise J. Barber, Georgios Laliotis, Avani Athauda, Benjamin Challoner, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Charuta Palsuledesai, Meenakshi Malhotra, Minetta Liu, Adham Jurdi, Shruti Sharma, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Robert M. Genta, Kevin O. Turner, Cristian Robiou, Anuradha Singhal, Massimo Rugge
Summary: Incomplete intestinal metaplasia is more prevalent in conditions (H. pylori gastritis) known to carry a higher risk of gastric cancer, and is strongly associated with its extension. However, the prevalence of incomplete IM is low in conditions (autoimmune atrophic gastritis and reactive gastropathy) known to have a low risk of gastric cancer.
DIGESTIVE DISEASES
(2023)